Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with recessive dystrophic epidermolysis bullosa. The approval is based on the pivotal ...
DUBLIN, Ireland, and Boston MA, April 22, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for ...
EXTON, Pa. and GERMANTOWN, Md., Sept. 25, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results